International Journal of Radiation Oncology * Biology * Physics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Initial Experience of Proton-Based Stereotactic Body Radiotherapy for Head and Neck Reirradiation
Up to 50% of patients with head and neck cancer (HNC) may recur after initial treatment, which often includes a combination of surgery, chemotherapy, and radiation. Reirradiation is an effective treatment option with high rates of local control. Hypofractionated regimens may be desirable due to high biologically effective doses, however they can be complicated by high rates of toxicity. Intensity-modulated proton therapy (IMPT) plans have dosimetric advantages compared to standard photon plans. We sought to review initial patient tolerance and treatment outcomes of proton-based stereotactic body radiotherapy (SBRT) for rei...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N. Ali, D. Bohannon, J. Zhou, M.W. McDonald, W.A. Stokes, S. Rudra, J.S. Remick, S. Tian, J.E. Bates Tags: 146 Source Type: research

Characteristics and Survival of Patients with Primary and Secondary Distant Metastasis of Oropharyngeal Squamous Cell Carcinoma (OPSCC)
OPSCC generally carries a favorable prognosis, particularly for HPV+ patients. However, distant metastasis (DM) occurs in 15-20% of patients. Most DM occurs following curative-intent treatment, but a proportion of patients present with primary DM. We sought to describe the characteristics and survival of patients with primary vs secondary DM OPSCC, including differences in the clinical presentation and prognosis from the time of presentation with DM. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: P.W. McGarrah, T.J. O'Byrne, C.N. Abdel-Halim, C. Fazer-Posorske, H. Fuentes Bayne, M.A. Neben-Wittich, S.C. Lester, D.J. Ma, J.M. Wilson, M.E. Gamez, D.L. Price, K.K. Tasche, L.X. Yin, E.J. Moore, K.M. Van Abel, K. Price Tags: 147 Source Type: research

FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab  + cetuximab in pts w/ recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
For patients with R/M HNSCC, current treatments are palliative with anti-PD-1 checkpoint inhibitor +/- platinum and 5-fluorouracil chemotherapy for first-line followed by taxanes, methotrexate, and cetuximab as later-line options. The median overall survival (OS) for R/M patients is 10-13 months, and those with HPV-negative HNSCC face the worst outcomes.[1] Ficlatuzumab is a humanized IgG1 mAB against HGF, the ligand for the c-MET tyrosine kinase receptor. HGF/c-MET pathway dysregulation is frequently observed in HPV-negative HNSCC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J. Bauman, K. Allman, R.I. Haddad Tags: 148 Source Type: research

Safety and Toxicity of Iopofosine I-131 with External Beam Radiation Therapy (EBRT) in Recurrent or Metastatic Head and Neck Cancer (HNC): Results of a Phase 1 Study
Retreatment of recurrent HNC is often limited by tumor adherence to critical structures or normal tissue tolerance to radiation therapy. Iopofosine I-131 (CLR 131) is a novel targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to malignant tumor cells optimized through specialized regions called lipid rafts. Radiation exposure is selective to cancer cells due to the interaction of the PLE with the highly enriched lipid rafts of the plasma membrane, which are non-reliant on cell surface markers. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.Y. Bruce, A. Burr, R.J. Kimple, M. Yu, D. Trask, S. Piaskowski, K. Oliver, J. Longcor, S.Y. Cho, B. Bednarz, P.M. Harari Tags: 149 Source Type: research

Deep Learning-Based Prognostic Prediction for Early Stage Laryngeal Cancer Patients Post-Radiotherapy: Utilizing 3D CBCT and EMR Data
Radiation therapy is a predominant treatment method for early-stage laryngeal cancer patients. The primary objective of this study is to predict the prognosis of recurrence in this specific patient group. Our study cohort comprises patients with stages 0-2, who have undergone radiation therapy with a curative intent rather than for palliative care. In this research, we endeavor to introduce a deep learning-based survival analysis model that harnesses data from multiple modalities obtained during radiation therapy. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.H. Lim, J. Heo, O.K. Noh Tags: 150 Source Type: research

Outcomes and Genomic Landscape of Patients Treated with Re-Irradiation for Recurrent Head and Neck Cancer Using Pencil Beam Scanning Proton Therapy: The Maryland Proton Treatment Center Experience
We describe clinical outcomes and toxicity of pencil beam scanning proton therapy (PBS-PT) for recurrent HNC, and report genomic alterations associated with patterns of failure to improve clinical decision making. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R.F. Krc, W. Mendes, J.K. Molitoris, M. Ferris, Y. Song, A.C. Shetty, R. Mehra, J. Papadimitriou, K. Hatten, R. Taylor, J. Wolf, K. Sun, S.M. Bentzen, W.F. Regine, P.T. Tran, M.E. Witek Tags: 151 Source Type: research

Tumor Tissue Modified Viral HPV DNA Monitoring in Patients with Recurrent, Metastatic HPV-driven Oropharyngeal Cancer
Monitoring circulating tumor tissue modified viral (TTMV)-HPV DNA during post-treatment surveillance is a tool for detecting recurrence in patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). We investigated the utility of the assay to capture therapeutic response and predict survival outcomes in patients with recurrent, incurable or metastatic (R/M) disease. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G.J. Hanna, J.N. Lukens, J. Jabalee, E.M. Rettig, M. Posner, K. Misiukiewicz, E. Genden, L. Sun, Z. Belal, E. MacDuffie, S. Roof Tags: 152 Source Type: research

Re-irradiation After Osteocutaneous Free Flap Reconstruction for Locally Recurrent Head and Neck Cancer: A Case Series
Recurrent head and neck cancer (HNC) poses difficult management. Salvage surgery is often used in these situations. However, even after salvage surgery, many patients are still considered high-risk for further recurrence and benefit from re-irradiation. Free flaps not only enable reconstruction following salvage surgery, but there have also been limited studies suggesting free flap reconstruction may reduce the amount of re-irradiation complications. There are no studies to date specifically examining the effects of osteocutaneous free flap reconstruction upon re-irradiation toxicity. (Source: International Journal of Radi...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: S. Gondi, K. Reichl, P. Tassone Tags: 153 Source Type: research

Cemiplimab and Metronomic Chemotherapy in Recurrent/Metastatic (R/M) Squamous Cell Carcinoma (SCC) of the Head and Neck (H & N): Trial in Progress.
The current first-line standard of care for recurrent/metastatic head and neck (H&N) squamous cell carcinoma (SCC) is anti-programmed death-ligand 1 (anti-PD-L1) immune checkpoint inhibition. Metronomic chemotherapy, low-dose high-frequency dosage aims to enhance immunomodulation, inhibit angiogenesis, and mitigate chemotherapy-related complications. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: F. Rind, P. Bhateja, C. Verschraegen, N. Seim, S. Baliga, E. Gogineni, D.J. Konieczkowski, M. Old, J.W. Rocco, D.M. Blakaj, M. Bonomi Tags: 154 Source Type: research

Mapping Key Clinical Trial Eligibility Criteria (EC) to Real-world Data (RWD): An Example Using KENYOTE-48
Extrapolating Randomized Clinical Trials (RCTs) evidence to the overall population is methodologically challenging. Here, we applied a novel methodology to map key EC from KEYNOTE-48 to patients initiating 1L pembrolizumab using RWD. Instead of filtering real-world patients based on EC which can rapidly shrink the sample size, we propose creating an augmented population to improve the power of RWD analyses. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: D. Zheng, T. Jemielita, L. Ai, C.M. Black, G.M. Hair Tags: 155 Source Type: research

Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
The phase 3 KEYNOTE-412 study (NCT03040999), pembro  + CRT (pembro arm) showed a trend toward improved EFS vs placebo + CRT (pbo arm) in pts with LA HNSCC, although the difference was not statistically significant (HR, 0.83 [95% CI, 0.68-1.03]; P=0.0429 [superiority threshold, P=0.0242]). Prespecified HRQoL outcomes from KEYNOTE-412 are prese nted. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.P. Machiels, Y. TAO, B. Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P. Figueiredo Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, S. Laban, R. Greil, M. Burian, M. Hetnal, L. Licitra, C.M. Black, J. Norquist, B. Gumuscu, B. Bidadi, L.L. Siu Tags: 156 Source Type: research

Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study
Pembrolizumab as monotherapy or in combination with chemotherapy is a standard of care in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) and PD-L1 CPS ≥1. While pembrolizumab monotherapy results in low response rates, the addition of 5FU/cisplatin adds significant toxicity for pts. Rational combinations which improve outcomes while avoiding cytotoxic chemotherapy are needed. HNSCC is associated with overexpression of VEGFR, MET, and AXL, and the re are preclinical data supporting the antitumor effect of inhibition of these kinases through suppressing tumor growth and angiogen...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.F. Saba, K. Harrington, L. Licitra, J.P. Machiels, M. Huang, F. Xu, P. Patel, R.I. Haddad Tags: 157 Source Type: research

Outcome of Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Post-Immune Checkpoint Inhibitor (ICI) Treatment
This study examines the efficacy of cetuximab as a subsequent treatment. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.C. Park, R.D. Merkin, L. Wirth, M.J. Patel, T.J. Roberts Tags: 158 Source Type: research

Weekly Paclitaxel, Carboplatin, and Cetuximab (PCC) as Treatment for Recurrent or Metastatic Head and Neck Squamous-cell Carcinoma (RM-HNSCC) that Progressed on Immune Checkpoint Inhibitors (ICI): A Retrospective Analysis
We report the outcomes of pts treated with weekly PCC after progression on ICI. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Bonomi, H. Abu-Sbeih, B. Klamer, M. Issa, F. Rind, K. Dibs, D.J. Konieczkowski, E. Gogineni, J. Pan, M. Old, E. Tili, A. Chakravarti, J.C. Grecula, S. Baliga, R. Carrau, J.W. Rocco, D.M. Blakaj, P. Bhateja Tags: 159 Source Type: research

Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study
Pembrolizumab monotherapy and pembrolizumab plus platinum-based chemotherapy are the standard of care for first-line treatment of R/M HNSCC. However, there is a growing unmet need for safe and efficacious treatment options for patients with R/M HNSCC whose disease progressed on or after platinum-based chemotherapy and immunotherapy. The randomized, open-label, phase 2 LEAP-009 (NCT04428151) study is being conducted to evaluate the safety and efficacy of lenvatinib plus pembrolizumab or lenvatinib monotherapy versus chemotherapy in patients with R/M HNSCC whose disease progressed after treatment with platinum-based therapy ...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K. Harrington, H.R. Kim, S. Salas, M. Oliva, R. Metcalf, M. Bernsdorf, J.W. Kim, E. Cohen, L.L. Siu, D. Rischin, L. Licitra, J. Vermorken, Q.T. Le, M. Tahara, J.P. Machiels, K. O'Hara, K. Pathiraja, B. Gumuscu, B. Bidadi, B. Burtness Tags: 160 Source Type: research